Europe Hepatitis B Infection Market
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2031 |
 市場規模（基準年） |
USD 3.13 Billion |
 Market Size (Forecast Year) |
USD 4.52 Billion |
 CAGR |
% |
| 主要市場プレーヤー |
Europe Hepatitis B Infection Market, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery- Industry Trends and Forecast to 2031
Europe Hepatitis B Infection Market Analysis and Insights
Data Bridge Market Research analyzes that the Europe hepatitis B infection market is expected to reach USD 4.52 billion by 2031 from USD 3.13 billion in 2023, growing with a CAGR of 4.7% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2016–2021) |
|
Quantitative Units |
Revenue in USD Billion |
|
Segments Covered |
Type (Chronic and Acute), Treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery |
|
Countries Covered |
Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe |
|
Market Players Covered |
Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), Merck Sharp and Dohme Corp. (U.S.), Novartis AG (Switzerland), Arrowhead Pharmaceuticals Inc. (U.S.), Arbutus Biopharma (Canada), Teva Pharmaceuticals, Inc. (Israel), Zydus Pharmaceuticals (India), Aurobindo Pharma (India), Lupin Pharmaceuticals, Inc. (India) |
Market Definition
The Europe hepatitis B infection market refers to the healthcare sector focused on the diagnosis, treatment, prevention, and management of hepatitis B virus (HBV) infections. This market encompasses a wide range of products and services, including vaccines, antiviral drugs, diagnostic tests, immune modulators, and therapeutics aimed at addressing both acute and chronic forms of hepatitis B. Hepatitis B is a highly infectious liver disease caused by the HBV, which can lead to severe health complications like cirrhosis, liver failure, and hepatocellular carcinoma. The market includes pharmaceutical companies, biotechnology firms, diagnostic service providers, healthcare facilities, and research institutions working to develop advanced treatment solutions. The increasing prevalence of hepatitis, coupled with rising awareness and government initiatives to curb its spread, are key drivers of market growth. Also, technological advancements in diagnostic tools and novel therapies, such as nucleoside analogs and immunomodulatory agents, are expanding the treatment landscape.
Europe Hepatitis B Infection Market Dynamics.
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
- increasing prevalence of Hepatitis B infections
The increasing prevalence of Hepatitis B infections serves as a significant driver in the Europe Hepatitis B infection market by creating a growing demand for effective diagnostic tools, vaccines, and antiviral treatments. As Hepatitis B is a major cause of liver diseases such as cirrhosis and liver cancer, the rising infection rates, particularly in regions with inadequate healthcare infrastructure, have heightened the need for prevention, management, and treatment options. The spread of chronic Hepatitis B infections, especially in low- and middle-income countries where awareness and vaccination programs are less established, further amplifies the market for immunization, antiviral therapies, and advanced diagnostic techniques. Also, pharmaceutical companies are investing in research and development of newer, more efficient antiviral drugs and vaccines to address the evolving strains of the virus. The rise in both acute and chronic cases, particularly in high-risk populations, has put pressure on healthcare systems to invest in improved diagnostics, vaccines, and antiviral therapies.
Restraint
- Side Effects and Drug Resistance
- Side effects and drug resistance serve as significant restraints in the Europe Hepatitis B infection market by limiting the effectiveness and long-term use of available therapies. Many antiviral drugs used to treat Hepatitis B can cause adverse effects such as fatigue, nausea, liver toxicity, and kidney damage, which can lead to poor patient adherence and treatment discontinuation. This not only hampers the success of treatment but also reduces the overall demand for certain medications. Furthermore, the development of drug-resistant strains of the Hepatitis B virus presents another major challenge, as it reduces the efficacy of current antiviral therapies and necessitates the constant development of new drugs. As resistance to existing treatments increases, it creates barriers for healthcare providers in managing the infection effectively, limiting the market's growth potential. These challenges contribute to hesitancy in prescribing long-term antiviral therapies, slowing the adoption of certain medications and thereby restraining market expansion
Opportunity
- Rising New Drug Releases and Increasing New Drug Permits for Hepatitis B
The hepatitis B market is experiencing significant growth, driven by several key factors including the rising number of new drug releases and an increase in new drug permits. The surge in drug approvals is partly a response to the persistent need for more effective antiviral therapies and vaccines to manage and potentially eradicate hepatitis B. This trend is evident from the increased investments in research and development by major pharmaceutical companies, which are focusing on innovative treatment options that offer improved efficacy, fewer side effects, and enhanced patient compliance. Additionally, advancements in drug delivery systems and the development of combination therapies have contributed to the expansion of the market. The growth in market share for hepatitis B drugs is also supported by the increasing Europe prevalence of the disease, particularly in regions with high infection rates such as Asia-Pacific and sub-Saharan Africa. As new therapies become available and the market becomes more competitive, financial growth is expected to be robust, with projections indicating a substantial increase in market value over the coming years. This growth is underpinned by rising healthcare expenditure, broader healthcare access, and heightened awareness about the importance of hepatitis B management. The market is likely to see continued expansion as new players enter the field, existing companies innovate, and healthcare systems around the world prioritize hepatitis B treatment.
Challenge
- The Cost of Hepatitis B Treatments is High
Recent Developments
- In September 2024, Gilead Sciences and Genesis Therapeutics announced a strategic collaboration to discover and develop novel small molecule therapies using Genesis’ GEMS AI platform. Gilead gained exclusive rights to develop and commercialize products from this partnership
- In July 2024, Gilead Sciences, Inc. presented research data, showcasing long-term efficacy and safety of Biktarvy in diverse HIV populations, including Hispanic/Latine individuals and older adults with comorbidities. Investigational once-daily and weekly dosing regimens were also highlighted
- In February 2024, GSK completed its acquisition of Aiolos Bio, including the promising AIO-001 monoclonal antibody for severe asthma. GSK paid USD 1000 million upfront and up to USD 400 million in milestone payments, expanding its respiratory biologics portfolio
Europe Hepatitis B Infection Market Scope
Europe hepatitis B infection market is categorized into two notable segments which are based on the type and treatment. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Chronic
- Acute
On the basis of type, market is segmented into chronic and acute.
Treatment
- Vaccine
- Antiviral Drugs
- Immune Modulator Drugs
- Surgery
On the basis of treatment, market is segmented into vaccine, antiviral drugs, immune modulator drugs, and surgery.
Europe Hepatitis B Infection Market Regional Analysis/Insights
Europe hepatitis B infection market is categorized into two notable segments which are based on the type and treatment.
The country covered in this market report are Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe.
Germany is expected to dominated the market due to technological advancements in diagnostics.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and, Europe Hepatitis B Infection Market Dynamics Market Share Analysis
Europe hepatitis B infection market dynamics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the market are Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), Merck Sharp and Dohme Corp. (U.S.), Novartis AG (Switzerland), Arrowhead Pharmaceuticals Inc. (U.S.), Arbutus Biopharma (Canada), Teva Pharmaceuticals, Inc. (Israel), Zydus Pharmaceuticals (India), Aurobindo Pharma (India), Lupin Pharmaceuticals, Inc. (India).
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE HEPATITIS B INFECTION MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 EUROPE HEPATITIS B INFECTION MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.2 NORTH AMERICA REGULATORY SCENARIO
5.3 EUROPE REGULATORY SCENARIO
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.5 SOUTH AMERICA REGULATORY SCENARIO
6 PIPELINE ANALYSIS
7 EPIDEMILIOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION
8.3 OPPORTUNITY
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS
8.4 CHALLENGES
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS
9 EUROPE HEPATITIS B INFECTION MARKET, BY TYPE
9.1 OVERVIEW
9.2 CHRONIC
9.3 ACUTE
10 EUROPE HEPATITIS B INFECTION MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 VACCINE
10.2.1 HOSPITAL PHARMACIES
10.2.2 DRUGS STORES AND RETAIL PHARMACIES
10.2.3 ONLINE PHARMACIES
10.3 ANTIVIRAL DRUGS
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF)
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF)
10.3.3 ENTECAVIR
10.3.4 OTHERS
10.4 IMMUNE MODULATOR DRUGS
10.4.1 PEGYLATED INTERFERON
10.4.2 INTERFERON ALPHA
10.5 SURGERY
11 EUROPE HEPATITIS B INFECTION MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 U.K
11.1.3 TURKEY
11.1.4 RUSSIA
11.1.5 SPAIN
11.1.6 ITALY
11.1.7 SWEDEN
11.1.8 BELGIUM
11.1.9 POLAND
11.1.10 FRANCE
11.1.11 SWITZERLAND
11.1.12 NETHERLANDS
11.1.13 NORWAY
11.1.14 DENMARK
11.1.15 FINLAND
11.1.16 REST OF EUROPE
12 EUROPE HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GILEAD SCIENCES, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 GLAXOSMITHKLINE PLC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 DYNAVAX TECHNOLOGIES CORPORATION
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 F. HOFFMAN-LA ROCHE LTD.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BRISTOL-MYERS SQUIBB COMPANY
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ARROWHEAD PHARMACEUTICALS, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 ARBUTUS BIOPHARMA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT UPDATES
14.8 AUROBINDO PHARMA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT UPDATES
14.9 LUPIN PHARMACEUTICALS, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT UPDATES
14.1 MERCK & CO., INC.,
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 NOVARTIS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 TEVA PHARMACEUTICAL INDUSTRIES
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 ZYDUS PHARMACEUTICALS, INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 REVENUE
14.13.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
表のリスト
TABLE 1 EUROPE CLINICAL TRIAL AND PIPELINE A-LYSIS AS PER THE COMPANY
TABLE 2 DISTRIBUTION OF PRODUCTS OR PROJECTS BY PHASE
TABLE 3 COUNTRY WISE EPIDEMIOLOGY FOR HEPATITIS B
TABLE 4 COST OF HEPATITIS B MEDICATIONS: BRAND VS. GENERIC PRICES
TABLE 5 EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 EUROPE CHRONIC IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 EUROPE ACUTE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 EUROPE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 EUROPE VACCINE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 EUROPE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 11 EUROPE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 EUROPE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 13 EUROPE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 EUROPE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 15 EUROPE SURGERY IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 EUROPE HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 17 EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 18 EUROPE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 19 EUROPE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 20 EUROPE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 21 EUROPE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 22 GERMANY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 GERMANY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 24 GERMANY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 25 GERMANY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 26 GERMANY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 27 U.K. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 U.K. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 29 U.K. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 30 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 31 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 32 TURKEY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 TURKEY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 34 TURKEY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 35 TURKEY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 36 TURKEY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 37 RUSSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 RUSSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 39 RUSSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 40 RUSSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 41 RUSSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 SPAIN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 SPAIN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 44 SPAIN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 45 SPAIN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 46 SPAIN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 47 ITALY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 ITALY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 49 ITALY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 50 ITALY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 51 ITALY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 52 SWEDEN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 SWEDEN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 54 SWEDEN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 55 SWEDEN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 56 SWEDEN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 57 BELGIUM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 BELGIUM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 59 BELGIUM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 60 BELGIUM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 61 BELGIUM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 62 POLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 POLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 64 POLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 65 POLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 66 POLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 67 FRANCE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 FRANCE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 69 FRANCE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 70 FRANCE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 71 FRANCE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 72 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 74 SWITZERLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 75 SWITZERLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 76 SWITZERLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 77 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 79 NETHERLANDS ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 80 NETHERLANDS IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 81 NETHERLANDS VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 82 NORWAY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 84 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 85 NORWAY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 86 NORWAY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 87 DENMARK HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 DENMARK HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 89 DENMARK ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 90 DENMARK IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 91 DENMARK VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 92 FINLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 FINLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 94 FINLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 95 FINLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 96 FINLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 REST OF EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
図表一覧
FIGURE 1 EUROPE HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 2 EUROPE HEPATITIS B INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HEPATITIS B INFECTION MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HEPATITIS B INFECTION MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HEPATITIS B INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HEPATITIS B INFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE HEPATITIS B INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE HEPATITIS B INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE HEPATITIS B INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE EUROPE HEPATITIS B INFECTION MARKET, BY TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 EUROPE HEPATITIS B INFECTION MARKET
FIGURE 15 CHRONIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HEPATITIS B INFECTION MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 BURDEN OF HBV INFECTION IN THE GENERAL POPULATION BY WHO REGION, 2019
FIGURE 18 EUROPE HEPATITIS B INFECTION MARKET: BY TYPE, 2023
FIGURE 19 EUROPE HEPATITIS B INFECTION MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 20 EUROPE HEPATITIS B INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 EUROPE HEPATITIS B INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 EUROPE HEPATITIS B INFECTION MARKET: BY TREATMENT, 2023
FIGURE 23 EUROPE HEPATITIS B INFECTION MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 24 EUROPE HEPATITIS B INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 EUROPE HEPATITIS B INFECTION MARKET BY TREATMENT, LIFELINE CURVE
FIGURE 26 EUROPE HEPATITIS B INFECTION MARKET, SNAPSHOT
FIGURE 27 EUROPE HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
